How R&D organizations can leverage FDA’s final guidance on pre-approval information exchange (PIE) to engage with payers prior to approval and launch.
Dean Hakanson, Jon Gonzales, and Tara Alire
Advertisement
Dean Hakanson, Jon Gonzales, and Tara Alire
Articles by Dean Hakanson, Jon Gonzales, and Tara Alire
R&D organizations can leverage FDA’s final guidance on pre-approval information exchange, otherwise known as PIE, to engage with payers prior to regulatory approval and commercial launch.
Advertisement
Latest Updated Articles
PIE is Good for You: Drive Patient Access by Embracing FDA's Final GuidancePublished: July 1st 2019 | Updated:
- Using FDA’s ‘PIE’ Recipe to Enhance Patient Access
Published: August 1st 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer’s Proven Playbook: Buy, Partner, Scale, Spin-Off, Optimize
2
Bristol Myers Squibb Expands its Strategic Collaboration with Sarah Cannon Research Institute
3
HHS and FDA Appoint Richard Pazdur as Director of The Center for Drug Evaluation and Research
4
AstraZeneca Stock Becomes UK’s Biggest Stock
5
